Huntington Square, NY, United States of America

Adrian R Krainer

This inventor holds 14 USPTO granted patents and 22 published patent applications, plus 1 CIPO patent and 9 EPO patents, primarily in Antisense Technology. Top assignees: Cold Spring Harbor Laboratory, Ionis Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc.. Active years: 2013-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adrian R Krainer. Retrieved from https://idiyas.com/inventor/adrian-r-krainer

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 22)

% Patents Active = 100.0

CIPO Patents = 1

EPO Patents = 9 (Patent Applications = 15)

Average Co-Inventor Count = 3.3

ph-index = 6

Forward Citations = 161(Granted Patents)

Location History:

Huntington Square, NY (US) (2015 - 2017)
East Northport, NY (US) (2021)
Hungtington Station, NY (US) (2021)
Huntington Station, NY (US) (2013 - 2022)

Company Filing History:

11 out of 197

Cold Spring Harbor Laboratory

patents

4 out of 291

Ionis Pharmaceuticals, Inc.

patents

3 out of 1,035

Isis Pharmaceuticals, Inc.

patents

4. 2 out of 10

Stoke Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2013-2022

Loading Chart...

Areas of Expertise:

Antisense Compounds

MRNA Decay

IKBKAP Splicing

SMN2 Splicing

Nuclear Gene Output

Oligomers

Protein Interaction

Genetic Disorders

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11352624 - Reducing nonsense-mediated MRNA decay (2022-06-07),

2. 11236330 - Antisense compounds and uses thereof (2022-02-01),

3. 11096956 - Antisense oligomers and uses thereof (2021-08-24),

4. 11083745 - Antisense oligomers for treatment of autosomal dominant mental retardation-5 and Dravet Syndrome (2021-08-10),

5. 11066668 - Compositions and methods for modulation of IKBKAP splicing (2021-07-20),

6. 10696969 - Targeted augmentation of nuclear gene output (2020-06-30),

7. 10647983 - Reducing nonsense-mediated mRNA decay (2020-05-12),

8. 10344282 - Compositions and methods for modulation of IKBKAP splicing (2019-07-09),

9. 9976143 - Targeted augmentation of nuclear gene output (2018-05-22),

10. 9717750 - Compositions and methods for modulation of SMN2 splicing in a subject (2017-08-01),

11. 9518259 - Compounds and methods for modulating interaction between proteins and target nucleic acids (2016-12-13),

12. 8980853 - Compositions and methods for modulation of SMN2 splicing in a subject (2015-03-17),

13. 8946183 - Compositions and methods for modulation of SMN2 splicing (2015-02-03),

14. 8361977 - Compositions and methods for modulation of SMN2 splicing (2013-01-29),

Title: The Innovator Spotlight: Adrian R Krainer

Introduction: Adrian R Krainer, a renowned inventor in the field of genetics and molecular biology, hails from Huntington Square, NY (US). With an impressive portfolio of 14 patents, Krainer is a pioneering figure in developing cutting-edge treatments for genetic diseases and disorders.

Latest Patents: Krainer's latest patents showcase his commitment to advancing medical science through innovative gene-specific therapies. One of his recent patents focuses on reducing nonsense-mediated mRNA decay, offering a novel approach to treating diseases caused by nonsense mutations. Additionally, he has patented antisense compounds for modulating splicing of the pyruvate kinase M transcript, showing promise in the treatment of cancer-related symptoms.

Career Highlights: Krainer's illustrious career includes pivotal roles at esteemed institutions such as the Cold Spring Harbor Laboratory and Ionis Pharmaceuticals, Inc. His work has revolutionized the field of genetics, paving the way for groundbreaking advancements in targeted gene therapies.

Collaborations: Throughout his career, Krainer has collaborated with esteemed colleagues such as C Frank Bennett and Frank Rigo. Together, they have worked tirelessly to develop innovative solutions for complex genetic disorders, further solidifying Krainer's reputation as a visionary inventor in the medical research community.

Conclusion: In conclusion, Adrian R Krainer's contributions to the field of genetics and molecular biology have been nothing short of extraordinary. Through his groundbreaking patents and collaborative efforts, Krainer continues to drive forward progress in the development of gene-specific therapies, offering hope for the treatment of challenging genetic diseases.

Profile summary based on public USPTO records.